Product
reslizumab
1 clinical trial
2 indications
Indication
EosinophilsIndication
AsthmaClinical trial
An Open-Label Extension Study of Reslizumab 110-mg Fixed, Subcutaneous Dosing in Patients 12 Years of Age and Older With Severe Eosinophilic AsthmaStatus: Terminated, Estimated PCD: 2018-02-22